Plain-English translation of NCT07170475 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing the safety of a combination of and in people with early-stage Parkinson's disease. The study will give 24 participants one of four different dose strengths of this medication combination, taken twice daily for 12 weeks. Researchers want to make sure the treatment is safe and well-tolerated before testing whether it might help slow or improve Parkinson's symptoms in future studies.
Current Parkinson's treatments help manage symptoms, but they don't slow the disease's progression. This medication combination may work through a new mechanism to protect nerve cells, and this early-stage safety study is a necessary first step before testing whether it could offer a real benefit to patients.
You likely qualify if…
You likely don't qualify if…
You would take the study medication by mouth twice daily (morning and evening) for 12 weeks. You would visit the clinic at the beginning and then at weeks 4, 8, and 12 for blood tests, physical exams, and brief questionnaires to check how you're doing. You would also keep a simple diary at home to note any side effects or changes in your daily activities.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Japan